Valence 로고
인기
로그인
Loading data for ENTA — first visit, this takes a few seconds.

관심목록에 추가

Enanta Pharmaceuticals In...

NasdaqGS: ENTA · 실시간 가격 · USD
13.50
-0.02 (-0.15%)
종가 기준: Aug 18, 2026, 3:59 PM

Enanta Pharmaceuticals Inc. (ENTA) Stock Price, Analysis & Data

-0.15%
매수호가9.75
시가총액393.19M
매출 (ttm)65.26M
순이익 (ttm)-63.23M
베타0.93
EPS (ttm)-2.42
P/E (ttm)n/a
선행 P/E-6.37
P/B (ttm)3.36
P/S (ttm)6.03
Earnings DateNov 16, 2026
매도호가17.08
거래량149,448
평균 거래량 (20일)208,630
시가13.48
전일 종가13.52
일중 범위13.27 - 13.67
52주 범위7.05 - 17.15
애널리스트n/a
목표주가n/a
배당n/a
배당락일n/a

ENTA 소개

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II c...

[더 보기]
산업 Biotechnology
섹터 Healthcare
IPO 일자 Mar 21, 2013
직원 수 120
상장 거래소 NasdaqGS
티커 ENTA
웹사이트 https://www.enanta.com
전체 기업 정보

재무 실적

2025년 Enanta Pharmaceuticals의 매출은 65.32M로, 전년 67.64M 대비 -3.42% 감소했습니다. 순이익은 -81.89M로, -29.43% 감소했습니다.

재무제표

어닝 서프라이즈

Enanta Pharmaceuticals가 Aug 10, 2026에 분기 실적을 발표했습니다:
  • 매출 $17.16M 예상치 하회 $0, 및 14.96% 전년 대비 성장.
  • EPS -0.67 예상치 하회 -0.16, 및 21.18% 전년 대비 성장.

    • 다음 실적 발표

    Enanta Pharmaceuticals Inc.의 실적 발표 예정일은 Nov 16, 2026, 정규장 중입니다.
    애널리스트 예상 매출은 ... 업그레이드
    news image

    1주 전 · Zacks

    Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates

    Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -81.08% and -20.97%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock...

    news image

    1주 전 · Zacks

    Coherus Oncology (CHRS) Reports Q2 Loss, Misses Revenue Estimates

    Coherus Oncology (CHRS) delivered earnings and revenue surprises of -337.50% and -45.57%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

    news image

    1개월 전 · Zacks

    Enanta Pharmaceuticals (ENTA) Moves 5.2% Higher: Will This Strength Last?

    Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the...

    news image

    3개월 전 · Zacks

    Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates

    Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of +2.17% and -2.26%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

    news image

    3개월 전 · Zacks

    Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates

    Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of +16.91% and -73.79%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock...

    2 페이지 중 1